What are Dexycu's Sales Figures?
Dexycu, a sustained-release postoperative pain medication, generated $3.6 million in net sales during the first quarter of 2023. This figure represents an increase from the $2.1 million in net sales reported for the same period in 2022 [1]. The drug's manufacturer, Harrow Health, reported these figures [1].
How is Dexycu Performing Commercially?
Harrow Health reported that Dexycu experienced strong demand in the first quarter of 2023, driven by an increasing number of hospitals and ambulatory surgery centers (ASCs) adopting the drug for their patients [1]. This increased adoption contributed to the growth in net sales [1].
What is Dexycu Used For?
Dexycu is a formulation of the opioid analgesic bupivacaine, designed for intraoperative, intrapleural, and perioperative instillation to manage postoperative pain [2]. It provides sustained release of the active ingredient, aiming to reduce the need for opioid medications after surgery [2].
Who Manufactures Dexycu?
Dexycu is manufactured and marketed by Harrow Health, Inc., a company focused on the ophthalmic and surgical markets [1][2]. Harrow Health acquired the rights to Dexycu from Íshana Therapeutics in 2020 [3].
When Did Dexycu Receive FDA Approval?
The U.S. Food and Drug Administration (FDA) approved Dexycu in May 2018 [2]. Harrow Health acquired the rights to the drug in April 2020 [3].
What Are Competitors to Dexycu?
While Dexycu offers a sustained-release opioid option for postoperative pain, other pain management strategies exist. These can include traditional opioid analgesics administered orally or intravenously, non-opioid pain relievers like NSAIDs and acetaminophen, and multimodal pain management approaches that combine different types of pain relief [4][5]. The competitive landscape also includes other investigational pain management therapies [6].
What is the Mechanism of Action for Dexycu?
Dexycu is a single-dose, non-opioid, sustained-release formulation of bupivacaine, a local anesthetic [2]. It is instilled during surgery and releases bupivacaine over a period of up to 72 hours, providing targeted pain relief at the surgical site [2].
What is the Regulatory Status of Dexycu?
Dexycu is approved by the U.S. Food and Drug Administration (FDA) for its intended use in managing postoperative pain [2].
What is the Outlook for Dexycu Sales?
Harrow Health has expressed optimism regarding Dexycu's market penetration and sales growth, citing increasing adoption in surgical settings [1]. The company anticipates continued demand as more healthcare providers recognize the benefits of its sustained-release pain management profile [1].
What Are the Potential Risks Associated with Dexycu?
As a formulation of bupivacaine, Dexycu carries potential risks associated with local anesthetics. These can include central nervous system and cardiovascular toxicity if administered intravenously or if there is systemic absorption [2]. Postoperative pain management strategies also carry general risks associated with opioid use, such as respiratory depression, addiction, and overdose, although Dexycu aims to mitigate these by reducing the need for systemic opioids [2][5].
What Are Other Products Offered by Harrow Health?
In addition to Dexycu, Harrow Health's portfolio includes other ophthalmic surgical products and pharmaceuticals [3]. Their focus is on addressing unmet needs in both the ophthalmic and broader surgical markets [2][3].
What is the History of Dexycu Ownership?
Dexycu was initially developed by Íshana Therapeutics and received FDA approval in 2018 [2][3]. Harrow Health acquired the rights to Dexycu from Íshana Therapeutics in April 2020 [3].
---
Sources:
[1] https://www.businesswire.com/news/home/20230509005565/en/Harrow-Health-Announces-First-Quarter-2023-Financial-Results
[2] https://www.dexycu.com/
[3] https://harrowinc.com/press-releases/news-details/2020/Harrow-Health-Announces-Acquisition-of-Dexycu-from-Ishana-Therapeutics/default.aspx
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836064/
[5] https://www.drugabuse.gov/publications/research-reports/nonmedical-prescription-pain-medicines/overview
[6] https://www.nature.com/articles/s41591-021-01612-2